CIDD 0067106
CIDD-0067106 is a selective mTORC1 pathway inhibitor targeting androgen receptor-positive (AR+) triple-negative breast cancer (TNBC). CIDD-0067106 demonstrates potent inhibition of AR+ TNBC cell lines with an GI50 value of 0.8 μM. CIDD-0067106 is promising for research of AR+ TNBC.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 2151865-39-1
- 화학식: C26H29N3O4
- 분자량:447.54
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
제품 설명
IC50 & Target
|
mTORC1 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A10 | GI50 |
35 μM
Compound: 30
|
Cytotoxicity against rat A10 cells assessed as growth inhibition incubated for 48 to 96 hrs by SRB method
Cytotoxicity against rat A10 cells assessed as growth inhibition incubated for 48 to 96 hrs by SRB method
|
[PMID: 29053266] |
| BT-549 | GI50 |
40 μM
Compound: 30
|
Cytotoxicity against human BT549 cells assessed as growth inhibition incubated for 48 to 96 hrs by SRB method
Cytotoxicity against human BT549 cells assessed as growth inhibition incubated for 48 to 96 hrs by SRB method
|
[PMID: 29053266] |
| HCC1806 | GI50 |
30 μM
Compound: 30
|
Cytotoxicity against human HCC1806 cells assessed as growth inhibition incubated for 48 to 96 hrs by SRB method
Cytotoxicity against human HCC1806 cells assessed as growth inhibition incubated for 48 to 96 hrs by SRB method
|
[PMID: 29053266] |
| HCC1937 | GI50 |
35 μM
Compound: 30
|
Cytotoxicity against human HCC1937 cells assessed as growth inhibition incubated for 48 to 96 hrs by SRB method
Cytotoxicity against human HCC1937 cells assessed as growth inhibition incubated for 48 to 96 hrs by SRB method
|
[PMID: 29053266] |
| MDA-MB-231 | GI50 |
50 μM
Compound: 30
|
Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition incubated for 48 to 96 hrs by SRB method
Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition incubated for 48 to 96 hrs by SRB method
|
[PMID: 29053266] |
| MDA-MB-453 | GI50 |
0.8 μM
Compound: 30
|
Cytotoxicity against human MDA-MB-453 cells assessed as growth inhibition incubated for 48 to 96 hrs by SRB method
Cytotoxicity against human MDA-MB-453 cells assessed as growth inhibition incubated for 48 to 96 hrs by SRB method
|
[PMID: 29053266] |
| SUM185PE | GI50 |
1.6 μM
Compound: 30
|
Cytotoxicity against human SUM185PE cells assessed as growth inhibition incubated for 48 to 96 hrs by SRB method
Cytotoxicity against human SUM185PE cells assessed as growth inhibition incubated for 48 to 96 hrs by SRB method
|
[PMID: 29053266] |
Chemical Information
-
CAS No. 2151865-39-1
-
분자량 447.54
-
화학식 C26H29N3O4
-
SMILES
C(C1=CC=C(C=2OC(=CN2)C3=CC=C(OCC=C(C)C)C=C3)N=C1)N4[C@H](C(OC)=O)CCC4
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocol
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)